ArticleFrontiers in microbiology2017
Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine.
Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 101 citations in OpenAlex.
- Yakuchinone B Ameliorates DSS-Induced Colitis by Modulating the Gut Microbiota-Metabolite Axis.Nutrients · 2026Article
- Preventive Effects of Probiotic and PostbioticJournal of microbiology and biotechnology · 2026Article
- Review
- Impact of ERAP1 downregulation on the pathogenesis of DSS-induced colitis and therapeutic response to sulfasalazine.Frontiers in immunology · 2025Article
- The gut microbiome regulates the clinical efficacy of sulfasalazine therapy for IBD-associated spondyloarthritis.Cell reports. Medicine · 2024Article
- Sturgeon-derived peptide LLLE alleviates colitis via regulating gut microbiota and its metabolites.Current research in food science · 2024Article
- Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.Microbiome research reports · 2023Article
- Manipulating Microbiota in Inflammatory Bowel Disease Treatment: Clinical and Natural Product Interventions Explored.International journal of molecular sciences · 2023Review
- Article
- Trans-Anethole Alleviates DSS-Induced Ulcerative Colitis by Remodeling the Intestinal Flora to Regulate Immunity and Bile Acid Metabolism.Mediators of inflammation · 2023Article
- Molecular Characterisation of Blood Microbiome in Patients with Ankylosing Spondylitis and Healthy Controls.Medical journal of the Islamic Republic of Iran · 2023Article
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status.Therapeutic advances in gastroenterology · 2023Article
- Research progress on the relationship between intestinal microecology and intestinal bowel disease.Animal models and experimental medicine · 2022Review
- Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease.Advances in nutrition (Bethesda, Md.) · 2022Review
- Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota.Stem cell research & therapy · 2022Article
- The promise of the gut microbiome as part of individualized treatment strategies.Nature reviews. Gastroenterology & hepatology · 2022Review
- Emerging story of gut dysbiosis in spondyloarthropathy: From gastrointestinal inflammation to spondyloarthritis.Frontiers in cellular and infection microbiology · 2022Review
- Article
- The influence of the gut microbiota on the bioavailability of oral drugs.Acta pharmaceutica Sinica. B · 2021Review
- Lactobacillus acidophilus LA5 improves saturated fat-induced obesity mouse model through the enhanced intestinal Akkermansia muciniphila.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) results from alterations in intestinal flora and the immune system. Sulfasalazine (SASP) is a sulfa antimicrobial used to treat IBD in clinic for years. However, how SASP affects gut microbes and its potential functions remains unclear. To investigate the relationships of SASP, IBD, and gut microbiome, we used 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce experimental colitis in rats, and analyzed the microbiota in the fecal samples, which come from the control group (treated with ethanol + saline), the model group (treated with TNBS-ethanol + saline) and the SASP group (treated with TNBS-ethanol + SASP), with 16S gene sequencing and followed up a subset sample using shotgun sequencing. The study found that SASP treatment could not only restore the TNBS-induced gut dysbiosis, which was proved by the increasing amount of SCFAs-producing bacteria and lactic acid-producing bacteria as well as the decreasing amount of Proteobacteria, but also modulate the dysregulated function of the TNBS-induced colitis to resemble that of the control group, including an increased capacity for basic metabolism (carbohydrate metabolism, citrate cycle) and a decrease in the oxidative stress (riboflavin, sulfur, cysteine) as well as bacterial pathogenesis (cell motility and secretion, bacterial motility proteins, flagellar assembly). Moreover, a higher proportion of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.